{"filing":{"accession_number":"0001213900-26-096263","cik":"0001075880","ticker":"KZIA","company_name":"KAZIA THERAPEUTICS LTD","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"ea0304307-6k_kazia.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026096263/ea0304307-6k_kazia.htm"},"events":[{"id":31053,"run_id":28477,"accession_number":"0001213900-26-096263","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Kazia announced preclinical and translational data for paxalisib in MSS/pMMR colorectal cancer, demonstrating tumor burden reduction and enhanced immunotherapy response, with plans to advance into a Phase 2 clinical trial beginning Q1 2027.","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":[{"id":33845,"accession_number":"0001213900-26-096263","item_number":"EX-99.1","item_title":"ea030430701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces preclinical and translational data for paxalisib in MSS/pMMR colorectal cancer, demonstrating tumor burden reduction and enhanced immunotherapy response, along with plans to advance into a Phase 2 clinical trial beginning Q1 2027. While the disclosure concerns a material clinical development milestone for the company's lead asset, it does not fit the discrete event categories (no earnings, M\u0026A, executive changes, or financial obligations). The announcement of preclinical efficacy data and the decision to initiate a new Phase 2 trial represents a significant operational and strategic milestone that would affect investor assessment of the company's pipeline progress and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:58:12.509985+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":31054,"run_id":28477,"accession_number":"0001213900-26-096263","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Kazia announced a material expansion of its paxalisib clinical development program into HR+/HER2- breast cancer, supported by preclinical data, with protocol amendment to its ongoing TNBC trial to add a three-arm expansion with first patient enrollment expected by end of 2026.","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":[{"id":33846,"accession_number":"0001213900-26-096263","item_number":"EX-99.2","item_title":"ea030430701ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a material expansion of Kazia's clinical development program for paxalisib into HR+/HER2- breast cancer, supported by preclinical data showing safety and antitumor activity. The company is amending its ongoing TNBC trial protocol to add a three-arm expansion with expected first patient enrollment by end of 2026 and full enrollment by end of 2027. This represents a significant operational and strategic milestone in the company's drug development pipeline that would affect a reasonable investor's assessment of the registrant's clinical progress and capital deployment strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:58:12.509985+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33845,"accession_number":"0001213900-26-096263","item_number":"EX-99.1","item_title":"ea030430701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces preclinical and translational data for paxalisib in MSS/pMMR colorectal cancer, demonstrating tumor burden reduction and enhanced immunotherapy response, along with plans to advance into a Phase 2 clinical trial beginning Q1 2027. While the disclosure concerns a material clinical development milestone for the company's lead asset, it does not fit the discrete event categories (no earnings, M\u0026A, executive changes, or financial obligations). The announcement of preclinical efficacy data and the decision to initiate a new Phase 2 trial represents a significant operational and strategic milestone that would affect investor assessment of the company's pipeline progress and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:58:12.509985+00:00","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-09-01"},{"id":33846,"accession_number":"0001213900-26-096263","item_number":"EX-99.2","item_title":"ea030430701ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a material expansion of Kazia's clinical development program for paxalisib into HR+/HER2- breast cancer, supported by preclinical data showing safety and antitumor activity. The company is amending its ongoing TNBC trial protocol to add a three-arm expansion with expected first patient enrollment by end of 2026 and full enrollment by end of 2027. This represents a significant operational and strategic milestone in the company's drug development pipeline that would affect a reasonable investor's assessment of the registrant's clinical progress and capital deployment strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:58:12.509985+00:00","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-09-01"}]}